Volume 11, Number 11—November 2005
Research
Neutralizing Antibody Response and SARS Severity
Mei-Shang Ho*, Wei-Ju Chen*, Hour-Young Chen†, Szu-Fong Lin†, Min-Chin Wang†, Jiali Di†, Yen-Ta Lu‡, Ching-Lung Liu‡, Shan-Chwen Chang§, Chung-Liang Chao¶, Chwan-Chuen King§, Jeng-Min Chiou*, Ih-Jen Su#, and Jyh-Yuan Yang†
Table 3
Laboratory confirmation of the reported 347 SARS-CoV–infected patients by neutralizing antibody (NT) or by RT-PCR*
| NT†/RT-PCR | No. (%) |
|---|---|
| Positive/positive | 121 (34.6) |
| Positive/negative or ND‡ | 126 (36.7) |
| Negative/positive | 32 (9.2) |
| ND‡/positive | 68 (19.7) |
*SARS-CoV, severe acute respiratory syndrome–associated coronavirus; RT-PCR, reverse transcription–polymerase chain reaction; ND, data not available.
†Positive = NT titer of >1:16 dilution; negative = NT titer <1:16 dilution.
‡Data not available because of loss to follow-up or insufficient number of specimens (n = 8), death (n = 55), or serum collected on the 3rd week (n = 5) of fever onset.
Page created: February 17, 2012
Page updated: February 17, 2012
Page reviewed: February 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.